US-based biopharmaceutical firm AbbVie has begun Phase II clinical trial programmes of its ABBV-8E12 antibody to treat patients with early Alzheimer's disease and progressive supranuclear palsy (PSP).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

ABBV-8E12 is an investigational humanised anti-tau antibody designed to target the tau protein, which is thought to stabilise intracellular structures necessary for maintenance and transport in neurons. 

Most of the neurodegenerative disorders such as Alzheimer's disease and PSP are reported to feature abnormal accumulation of altered tau protein.

The Phase II trial will evaluate the efficacy and safety of ABBV-8E12 in 400 early Alzheimer's patients to delay disease progression, while the study will assess the efficacy and safety of the drug in 180 adults to slow the progression of PSP.

See Also:

"We see potential in ABBV-8E12 and tau-focused approaches to progressive neurodegenerative diseases, such as early Alzheimer's disease and PSP."

AbbVie Foundational Neuroscience Center vice-president Eric Karran said "We see potential in ABBV-8E12 and tau-focused approaches to progressive neurodegenerative diseases, such as early Alzheimer's disease and PSP.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The initiation of the Phase II clinical trial programmes and the FDA's Fast Track Designation for PSP signify important steps forward in AbbVie's ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to patients."

The firm has reported positive results for the completed pre-clinical and Phase I studies of the drug in PSP and early Alzheimer's disease.

Licensed from C2N Diagnostics in 2015, ABBV-8E12 has secured fast track designation from the US Food and Drug Administration (FDA), as well as orphan drug designation from both FDA and European Medicines Agency (EMA) for PSP.

Image: AbbVie corporate headquarters. Photo: courtesy of AbbVie.